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The  toxicity  of Clostridium  difﬁcile  large  clostridial  toxin  B  (TcdB)  can  be  reduced  by  many  orders  of
magnitude  by  a combination  of  targeted  point  mutations.  However,  a TcdB  mutant  with  ﬁve  point  muta-
tions (referred  to  herein  as mTcdB)  still  has residual  toxicity  that  can be  detected  in  cell-based  assays
and  in-vivo  mouse  toxicity  assays.  This  residual  toxicity  can be effectively  removed  by  treatment  with
formaldehyde  in  solution.  Storage  of the formaldehyde-treated  mTcdB  as  a liquid  can  result  in reversion
over  time  back  to  the  mTcdB  level  of toxicity,  with  the  rate  of  reversion  dependent  on the  storage  tem-
perature.  We  found  that for  both  the  “forward”  mTcdB  detoxiﬁcation  reaction  with  formaldehyde,  and
the  “reverse”  reversion  to toxicity  reaction,  mouse  toxicity  correlated  with  several  biochemical  assays
including  anion  exchange  chromatography  retention  time  and appearance  on  SDS-PAGE.  Maintenance  of
a low  concentration  of  formaldehyde  prevents  reversion  to toxicity  in  liquid  formulations.  However,  when
samples with  0.016%  (v/v)  formaldehyde  were  lyophilized  and  stored  at 37 ◦C, formaldehyde  continued
to  react  with  and modify  the  mTcdB  in  the  lyophilized  state.  Lyophilization  alone  effectively  prevented
reversion  to toxicity  for formaldehyde-treated,  formaldehyde-removed  mTcdB  samples  stored  at  37 ◦C
for  6 months.  Formaldehyde-treated,  formaldehyde-removed  lyophilized  mTcdB  showed  no evidence  of
reversion  to toxicity,  appeared  stable  by  several  assays,  and was  immunogenic  in  mice, even  after  storage
for 6 months  at  37 ◦C.
ublis© 2014  The  Authors.  P
. Introduction
Toxoids have been used successfully as antigens in many com-
ercial and experimental vaccines, including for such diseases as
iphtheria, tetanus, and botulism, and for venomous snake bites
1,2]. Toxoids can be prepared through site-directed or chemically
nduced mutations in the toxin genetic sequence [3–5], by chemi-
al treatment of the toxin protein [1,6], or by combinations of those
pproaches [7–10]. Formaldehyde can react at many sites in pro-
eins, as recently described for insulin [11] and tetanus toxin [12].
any of the modiﬁcations were chemically reversible Schiff bases,
nd for several formaldehyde-treated toxoids, reversion to toxic-
ty has been observed [13–16]. For some toxins, inclusion with the
ormaldehyde of an amino acid such as lysine or glycine was shown
∗ Corresponding author. Tel.: +1 215 652 3533.
E-mail address: david thiriot@merck.com (D.S. Thiriot).
1 Bei Wang and Su Wang contributed equally to this work.
ttp://dx.doi.org/10.1016/j.vaccine.2014.06.032
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unhed  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND
license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
to increase the rate and extent of detoxiﬁcation and also minimize
reversion to toxicity [17–19].
Strains of Clostridium difﬁcile produce several toxins, includ-
ing the large clostridial toxin B (TcdB), which plays a signiﬁcant
role in C. difﬁcile disease [20]. C. difﬁcile toxoid-based vaccines
are in development, and toxoid approaches that employ genetic
manipulations (mutations, truncations, domain swaps, etc.) and/or
chemical treatments have been described [21–29]. Formaldehyde
treatment methods have been described, and include addition of
lysine [26] or glycine [27] with the formaldehyde during treatment.
Reversion to toxicity was  observed when formaldehyde-treated
non-mutant TcdA and TcdB [26] or triple-mutant TcdA and TcdB
[27] were stored as liquids after formaldehyde removal at elevated
temperatures (25–37 ◦C) for days to weeks. Reversion to toxicity in
liquid formulations could be prevented by maintaining or adding
back a low concentration of formaldehyde (0.010–0.020%) with the
toxoid vaccine antigen [26,27].
We have studied the formaldehyde detoxiﬁcation of a recom-
binant mutant of the large clostridial toxin B (referred to herein
as mTcdB). The mutations were selected based on previously
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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ublished reports [21–23] and reduce the toxicity versus non-
utant TcdB by many orders of magnitude. However, mTcdB
esidual toxicity is still measurable (before formaldehyde treat-
ent) in cell-based and in-vivo mouse toxicity assays. We
dentiﬁed biochemical assays that correlate with the extent of the
TcdB/formaldehyde residual detoxiﬁcation reaction, and could
etect reversion to toxicity better than a cell-based toxicity assay
ould in our hands. We  found that for formaldehyde treatment of
TcdB under the conditions we studied (room temperature for
–3 days), inclusion of lysine with the formaldehyde during mTcdB
reatment slowed the detoxiﬁcation reaction, and did not appear
o prevent reversion to toxicity. After formaldehyde removal, it
ppeared unnecessary to add back a low concentration of formalde-
yde to mTcdB samples prior to lyophilization as lyophilization
lone was effective at preventing reversion to toxicity, even when
oxoids were stored for 6 months at elevated temperatures. Mouse
mmunization studies showed that lyophilized toxoid samples
ere thermostable, with essentially no change detected in neutral-zing antibody titers after storage at 37 ◦C for 6 months. We  found
hat in samples that were lyophilized with 0.016% formaldehyde,
odiﬁcation of the toxoid continued in the lyophilized state when
tored at 37 ◦C. In mouse immunogenicity studies, such toxoid
able 1
TcdB formaldehyde detoxiﬁcation and reversion study groups, with mouse toxicity a
emonstrates that the mouse toxicity assay appears better able to detect reversion to tox
Group Duration of
formaldehyde
treatment
(days)
Lysine added
during
formaldehyde
treatment?
Physical form
during storage
Storage time
temperature
1 Not treated NO Frozen liquid 1 Month, −7
2  Not treated NO Lyo 1 Month, 2–
6 Months, 2–
3  1 NO Frozen liquid 1 Month, −7
4  1 YES Frozen liquid 1 Month, −7
5  1 NO Liquid 1 Month, 2–
6  1 NO Liquid 14 Days, 25 ◦
17 Days, 2–8
7  2 NO Liquid 14 Days, 25 ◦
17 Days, 2–8
8  3 NO Liquid 14 Days, 25 ◦
17 Days, 2–8
9  1 YES Liquid 14 Days, 25 ◦
17 Days, 2–8
10  2 YES Liquid 14 Days, 25 ◦
17 Days, 2–8
11  1 NO Liquid 7 Days, 25 ◦C
24 Days, 2–8
12  2 NO Liquid 7 Days, 25 ◦C
24 Days, 2–8
13  1 YES Liquid 7 Days, 25 ◦C
24 Days, 2–8
14  1 NO Lyo 1 Month, 2–
6 Months, 2–
15  1 NO Lyo 1 Month, 25
6 Months, 25
16  1 NO Lyo 1 Month, 37
6 Months, 37
17  1 YES Lyo 1 Month, 37
6 Months, 37
18  2 NO Lyo 1 Month, 37
6 Months, 37
19  2 YES Lyo 1 Month, 37
6 Months, 37
20  3 NO Lyo 1 Month, 37
6 Months, 37
21  1c NO Liquid 1 Month, 25
22  1c NO Lyo 1 Month, 37
6 Months, 37
a For non-mutant C. difﬁcile toxin B control, TC50 in the cell-based toxicity assay was 0.
b Non-toxic to the detection limit tested in the assay.
c In groups 21 and 22 only, 0.016% (v/v) formaldehyde was  added back after dialysis, an3 (2015) 252–259 253
appeared slightly less immunogenic than lyophilized toxoid stored
without formaldehyde.
2. Materials and methods
2.1. Construction, expression and puriﬁcation of mTcdB
Mutant TcdB (mTcdB) is based on the NAP1 strain R20291
TcdB wild type sequence (Genbank accession no. YP 003217086),
but includes ﬁve mutations: W102A, D288A, E515Q, W520A and
C698A. mTcdB was expressed using a baculovirus expression
system. The culture was  harvested approximately 5 days post-
infection. Following cell lysis with TRITON X-100, mTcdB was
puriﬁed using AEX, hydroxyapatite and hydrophobic interaction
chromatography.
2.2. mTcdB formulation, formaldehyde treatment, lyophilization,
storage, and reconstitutionmTcdB was formulated at 1.17 mg/mL  in 20 mM HEPES, 100 mM
NaCl, 0.01% polysorbate-80, pH 7.2. Residual detoxiﬁcation was
with 0.45% (v/v) formaldehyde with or without 30 mM  lysine at
nd cell-based toxicity results. Data from several groups (4, 6, 9, 10, 11 and 13)
icity than the cell-based toxicity assay.
 and Mouse deaths
when tested after
storage for 1 month
(0.5 mg/dose)
Cell-based TC50
after storage
for 1 month
(g/mL)a
Mouse deaths when
tested after storage
for 6 months
(0.5 mg/dose)
0 ◦C 6/6 0.151 Not tested
8 ◦C
8 ◦C
5/6 0.0746 6/6
0 ◦C 0/6 >500b Not tested
0 ◦C 4/6 >500b Not tested
8 ◦C 0/6 >500b Not tested
C+
◦C
5/6 >500b Not tested
C+
◦C
0/6 >500b Not tested
C+
◦C
0/6 >500b Not tested
C+
◦C
4/6 >500b Not tested
C+
◦C
5/6 >500b Not tested
+
◦C
2/6 >500b Not tested
+
◦C
0/6 >500b Not tested
+
◦C
4/6 >500b Not tested
8 ◦C
8 ◦C
0/6 >500b 0/6
◦C
◦C
0/6 >500b 0/6
◦C
◦C
0/6 >500b 0/6
◦C
◦C
0/6 >500b 0/6
◦C
◦C
0/6 >500b 0/6
◦C
◦C
0/6 >500b 0/6
◦C
◦C
0/6 >500b 0/6
◦C 0/6 >500b Not tested
◦C
◦C
0/6 >500b 0/6
00000364 g/mL.
d present during storage.
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oom temperature (20–25 ◦C) for 1–3 days. Samples were then
ialyzed overnight at 2–8 ◦C against 20 mM HEPES, 100 mM NaCl,
H 7.2 to remove formaldehyde and free lysine if present. For
wo samples (Groups no. 21 and no. 22 in Table 1), 0.016% (v/v)
ormaldehyde was added back after dialysis, before lyophilization
r storage. For formulations intended for lyophilization, sucrose
as added to 5% (w/v) and lyophilization performed using standard
ethods (described in Supplementary). Samples were stored at
70 ◦C, 2–8 ◦C, 25 ◦C, or 37 ◦C, as indicated in Table 1. Lyophilized
amples were reconstituted with water, resulting in ﬁnal concen-
rations of 1 mg/mL.
.3. Anion exchange (AEX) chromatography assay
Anion exchange chromatography (AEX) used the weak anion
xchange column Dionex ProPac WAX-10, 4 × 250 mm.  Mobile
hase A contained 10 mM sodium phosphate, pH 7.2 and mobile
hase B contained 10 mM  sodium phosphate with 1 M sodium chlo-
ide, pH 7.2. Samples were diluted to 0.1 mg/mL  in mobile phase A,
njected onto the column and equilibrated in 45% mobile phase B
or 7 min. The mTcdB samples were separated using a gradient of
ig. 1. The extent of the formaldehyde mTcdB detoxiﬁcation reaction and reversion to t
emperature. (A) Storage time as a liquid at room temperature (“reversion time”, after for
B)  Storage time as a liquid at room temperature (“reversion time”) correlates with a shift
oxicity. For samples that were treated with formaldehyde (without added lysine), a shift
he  formaldehyde detoxiﬁcation reaction and toxicity in mice. The symbols in the panel (
hysical form in which they were stored for 1 month prior to assay. (D) Sypro Orange th
re  the group numbers and refer to Table 1. They are color coded to indicate the physical 
ime,  an increase in the mTcdB dye-binding melting temperature appears to be a predicto3 (2015) 252–259
55–80% mobile phase B over 20 min  and washed with 100% mobile
phase B for 2 min  at 1 mL/min ﬂow rate.
2.4. Cell-based toxicity assay
The basis for this assay was  the morphological change that Vero
CCL-81 cells (ATCC) undergo when exposed to the toxoid, thus
triggering the cell-death pathways. Cell death was measured by
chemiluminescent detection. This signal was  then plotted and ﬁt
to a 4-parameter logistic curve to report a TC50.
2.5. Mouse immunogenicity studies and measurement of toxin
neutralizing titers in mouse sera
Mouse immunogenicity studies were conducted with C57BL/6
mice (female, 6–7 weeks old, 17–18 grams from Charles River,
Wilmington, MA). Water, food and daily care followed IACUC
guidance. Toxoid antigens were formulated with aluminum
hydroxyphosphate sulfate adjuvant (450 g Al/mL). Mice were
immunized (7 mice/group) on day 0, 7, 14 and 21 by intramuscu-
lar injection 50 L per quadricep (total volume 100 L, delivering
20 g mTcdB and 45 g aluminum.) Mice were bled at 1, 2, 4, and 6
oxicity can be monitored by changes in the AEX retention time and thermal melt
maldehyde treatment and formaldehyde removal) correlates with toxicity in mice.
 in the AEX retention time peak. (C) AEX peak retention time correlates with mouse
 to longer retention time on AEX appears to be a reliable predictor of the extent of
C) are the group numbers and refer to Table 1. They are color coded to indicate the
ermal melt temperature correlates with mouse toxicity. The symbols in the plots
form in which they were stored for 1 month prior to assay. Like AEX peak retention
r of the extent of the formaldehyde detoxiﬁcation reaction and toxicity in mice.
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eeks after the last immunization, and TcdB neutralizing titer was
easured for each mouse at each timepoint. The cell-based neutral-
zation assay was performed as described in Supplementary data
nd previously [30].
.6. Additional methods
Additional Materials and Methods details are described in Sup-
lementary.
. Results
.1. Reversion to toxicity is observed for formaldehyde-treated
TcdB toxoids stored as liquids
The toxicity of mTcdB before formaldehyde treatment, and
mmediately after 1- or 3-days formaldehyde treatment at room
emperature (without added lysine), was measured in mice as
escribed in Supplementary. Without formaldehyde treatment,
TcdB killed mice at moderate doses (LD50 ∼ 0.01 mg/dose), but
mmediately after formaldehyde treatment no mouse deaths
ig. 2. Formaldehyde treatment and reversion to toxicity detected by reducing SDS-PAGE
s  treated with formaldehyde. Reversion to toxicity correlates with the appearance of a
Composite image assembled from two SDS-PAGE gels.) (B) SDS-PAGE and mouse toxicit
reatment slows the residual detoxiﬁcation reaction and does not appear to prevent rever
nly  by the absence or presence of lysine during the formaldehyde treatment step. These 
rovides no clear beneﬁt toward the goal of detoxiﬁcation or preventing reversion, and is3 (2015) 252–259 255
occurred, even at 0.6 mg/dose (Supplementary Table 1). Detoxiﬁca-
tion of mTcdB was studied as a function of formaldehyde treatment
time, and reversion to toxicity could be observed (Supplementary
Fig. S-1). To study reversion to toxicity, twenty two toxoids were
prepared which differed in the duration of formaldehyde treat-
ment, the absence or presence of added lysine during formaldehyde
treatment, physical form and storage conditions (Table 1). In mouse
toxicity studies (0.5 mg/dose), control frozen liquid (Group 1) and
lyophilized (Group 2) mTcdB samples that had not been formalde-
hyde treated caused high levels of mouse deaths (6/6 or 5/6) as
expected. These samples also showed expected levels of toxicity
in a cell-based toxicity assay (TC50 approximately 0.0001 mg/mL).
mTcdB samples treated with formaldehyde for 1 day and stored
frozen (Group 3) or refrigerated (Group 5) for a month caused
no mouse deaths. However, liquid samples that were stored for
periods of time at 25 ◦C (7 or 14 days, Groups 11 and 6), showed
reversion to toxicity as mouse deaths occurred (Supplementary
Fig. S-2). Surprisingly, the cell-based toxicity assay was  not able
to detect this reversion to toxicity. While the cell-based assay is
highly sensitive and able to differentiate cell toxicity differences
over many orders of magnitude for TcdB and different TcdB mutants
. (A) A shift on SDS-PAGE to apparent higher molecular weight occurs when mTcdB
 broad series of bands that are partially shifted back to lower molecular weight.
y assays demonstrate that inclusion of 30 mM lysine during mTcdB formaldehyde
sion to toxicity in liquid formulations. Several pairs of samples in this study differed
selected examples illustrate that addition of lysine during formaldehyde treatment
 in fact counterproductive. (Composite image assembled from two SDS-PAGE gels.)
2 cine 33 (2015) 252–259
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Fig. 3. Lack of “reversion” of lyophilized formaldehyde-treated mTcdB samples
stored from 1 to 6 months at elevated temperatures, based on mouse toxicity and
AEX retention time shift. Storage temperature and time is coded by color and symbol,
as  indicated. Non-formaldehyde-treated samples are plotted at “0 days formalde-
hyde treatment”. (A) Mouse toxicity results. Non-formaldehyde-treated lyophilized
mTcdB stored 1 or 6 months resulted in mouse deaths. None of the formaldehyde-
treated lyophilized mTcdB samples resulted in mouse deaths, whether stored for 1
month or 6 months, even when stored at elevated temperatures. (B) The AEX reten-
tion time of formaldehyde-treated, lyophilized mTcdB stored for 6 months shows
no evidence of reversion toward the non-formaldehyde-treated retention time, but56 B. Wang et al. / Vac
efore formaldehyde treatment, in-vivo mouse toxicity assays were
uperior for detecting reversion to toxicity after formaldehyde
reatment (Table 1).
.2. The extent of the formaldehyde detoxiﬁcation reaction and
eversion to toxicity can be followed by shifts in anion exchange
hromatography retention time, thermal unfolding temperature,
nd SDS-PAGE
We  found that anion exchange chromatography (AEX) could
e used to monitor the extent of the mTcdB/formaldehyde reac-
ion. When mTcdB was treated with formaldehyde without added
ysine, the elution peak was broadened and the retention time
eak shifted to longer times. When lysine was included in the
ormaldehyde reaction, the AEX shifted in the opposite direction,
o a shorter retention time. A rationale for the AEX retention time
hifts is presented in Supplementary. For those samples to which
ysine was not added, the shift in the retention time peak correlated
ith formaldehyde reaction time (Supplementary Fig. S-3), and we
ound that AEX retention time peak shift could be used to mon-
tor both the “forward” detoxiﬁcation reaction and the “reverse”
eversion to toxicity reaction. For these samples, AEX shift cor-
elated with reversion time and with mouse deaths (Fig. 1A–C).
he thermal unfolding temperature of mTcdB and formaldehyde-
reated mTcdB (without added lysine) measured by a Sypro Orange
ye-binding assay also showed a similar correlation with toxic-
ty in mice (Fig. 1D). Reversion to toxicity could also be visualized
y SDS-PAGE (Fig. 2A). On SDS-PAGE, formaldehyde treatment of
TcdB results in an apparent shift to higher molecular weight.
eversion to a less-formaldehyde-modiﬁed and more toxic form of
TcdB appears as the partial shift back to lower apparent molec-
lar weight and a “ladder” appearance on the gel. The magnitude
f the shift, appearance of the “ladder”, and other analyses (includ-
ng Field Flow Fractionation, data not shown) appear consistent
ith the size increase being the result of the formation of many
ormaldehyde adducts, not the formation of a dimer. For samples
ithout added lysine, AEX retention time shift and SDS-PAGE had
reater predictive value for reversion to toxicity than the cell-based
oxicity assay.
To examine the effect of including an amino acid with the
ormaldehyde on detoxiﬁcation and reversion to toxicity, samples
f mTcdB were treated with formaldehyde and lysine. Inclusion
f lysine appeared to slow down the forward detoxiﬁcation reac-
ion, and did not appear to prevent reversion to toxicity in liquid
Fig. 2B). For samples that differed only in the presence or absence
f added lysine during formaldehyde treatment, SDS-PAGE showed
hat the presence of lysine resulted in less formaldehyde modiﬁca-
ion of the mTcdB and there were generally more mouse deaths. We
onclude that for the formaldehyde reaction conditions we  studied
room temperature for 1–3 days), adding lysine is not necessary
r helpful during formaldehyde treatment of mTcdB and can be
ounterproductive.
.3. Lyophilization effectively prevents formaldehyde-treated
TcdB reversion to toxicity for at least 6 months at elevated
emperatures
Lyophilized samples were tested after 1 month and 6 months of
torage at different temperatures (2–8 ◦C, 25 ◦C, and 37 ◦C) to look
or evidence of reversion to toxicity. The nine lyophilized groups
xamined included one control group that was not formaldehyde
reated (Table 1 Group 2), ﬁve groups treated with formaldehyde
lone (Table 1 Groups 14, 15, 16, 18, and 20), two groups treated
ith formaldehyde plus lysine (Table 1 Groups 17 and 19), and
ne group treated with formaldehyde without lysine and then dia-
yzed, to which a low concentration of formaldehyde (0.016% v/v)rather a small increase in retention time compared with samples stored for 1 month.
was added back before lyophilization (Table 1 Group 22). For all
the formaldehyde-treated lyophilized groups, there were no mouse
deaths and no evidence of toxicity in the cell-based assays following
1 month and 6 months of storage at any of the temperatures exam-
ined. In the lyophilized non-formaldehyde-treated control group
(Group 2), there were many mouse deaths (5/6 after 1 month and
6/6 after 6 months, Fig. 3A), and toxicity in the cell-based assay
was observed as expected (Table 1). For the ﬁve groups treated
with formaldehyde alone and the formaldehyde removed (Groups
14, 15, 16, 18, and 20), the shift in AEX retention time (Fig. 3B) and
the appearance on SDS-PAGE (Supplementary Fig. S-4) were essen-
tially the same at 1 and 6 months, showing no evidence of reversion
in the lyophilized samples. Storage of the pre-lyophilized “parent”
samples as liquids at 2–8 ◦C for 6 months did lead to signiﬁcant
reversion of the AEX shift (Supplementary Fig. S-5), demonstrat-
ing the stabilizing effect of lyophilization. Extending the time for
formaldehyde treatment would delay the reappearance of toxicity
for a formulation stored as a liquid, but based on the shift in AEX
retention time, it is clear that reversion in liquid still occurs, and
B. Wang et al. / Vaccine 33 (2015) 252–259 257
Fig. 4. Mouse immunogenicity studies. Lyophilized antigens were stored for 6 months at the indicated temperatures, reconstituted, then mixed with aluminum adjuvant
prior  to injection. Mice received 4 injections (at day 0, 7, 14, and 21) and geometric mean neutralizing titer was measured for each mouse at 1, 2, 4, and 6 weeks following
the  last immunization (post dose 4). Error bars show the geometric mean “*/” (times and divided by) the geometric standard error, calculated as described in Supplementary.
(A)  Formaldehyde-treated, lyophilized antigen stored for 6 months at different temperatures (2–8 ◦C, 25 ◦C, and 37 ◦C) gave similar immunogenicity, suggesting considerable
overall  thermal stability of the lyophilized antigen. (B) Antigen that was  treated with formaldehyde for 1, 2, or 3 days at room temperature showed similar immunogenicity. (C)
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tormaldehyde-treated antigen, to which 0.016% v/v formaldehyde was added back a
han  similarly treated antigen to which formaldehyde was  not added back prior to 
hat given enough storage time in liquid and depending on storage
emperature toxicity may  reemerge.
.4. Stability and immunogenicity of lyophilized
ormaldehyde-treated mTcdB
The immunogenicity of the lyophilized formaldehyde-treated
TcdB samples after 6 months storage at different tempera-
ures was tested in mice. Reconstituted samples were formulated
ith aluminum adjuvant and administered to mice in 4
eekly vaccinations. Serum toxin (TcdB) neutralizing titers were
easured at 1, 2, 4, and 6 weeks after the last immuniza-
ion. Both formaldehyde-treated and non-formaldehyde-treatedialysis before lyophilization, appeared slightly less immunogenic at each timepoint
lization.
antigens were immunogenic, however the immunogenicity of
non-formaldehyde-treated antigen (Group 2) was higher than
formaldehyde-treated antigen (Fig. 4). Storage of lyophilized
antigen for 6 months at different temperatures (2–8 ◦C, 25 ◦C, and
37 ◦C) had little impact on immunogenicity (Fig. 4A), suggesting
signiﬁcant thermal stability for the lyophilized antigen. Different
formaldehyde treatment times of 1, 2, or 3 days at room temper-
ature also had little impact on immunogenicity (Fig. 4B), which is
encouraging from the viewpoint of formaldehyde treatment pro-
cess robustness. The effect of adding back 0.016% formaldehyde
before lyophilization on immunogenicity was assessed by compar-
ing a pair of samples that differed only in that regard (Group 16 vs.
Group 22), and were otherwise prepared and stored in the same
258 B. Wang et al. / Vaccine 3
Fig. 5. Formaldehyde reaction with mTcdB in the lyophilized state. Adding a low
level of formaldehyde (0.016% v/v) prior to lyophilization results in lyophilized anti-
gen that continues to be progressively modiﬁed by formaldehyde in the lyophilized
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wtate for at least 6 months when stored at 37 ◦C. As this could change the vaccine
ver time and may  decrease immunogenicity (Fig. 4C), the potential for continuing
ormaldehyde modiﬁcation over time is at least of theoretical concern.
anner. In this comparison, the immunogenicity of the sample
ith 0.016% formaldehyde added back before lyophilization was
lightly lower at each of the timepoints measured (Fig. 4C).
Adding back 0.016% formaldehyde after dialysis, before
yophilization (Group 22) was found to have a dramatic and pro-
ressive effect on the AEX retention time. After 1 month storage at
7 ◦C, the AEX retention time was longer than for samples that did
ot have added back formaldehyde. After 6 months storage at 37 ◦C,
he AEX retention time was even longer still (Fig. 5). This suggests
hat the low level of formaldehyde added back before lyophiliza-
ion does not just maintain the “status quo” of the detoxiﬁcation
eaction immediately after it is completed, but can continue to
eact with and modify the antigen in the lyophilized state at that
emperature. We  did not have the corresponding sample stored at
◦C to assess this effect at refrigerated temperatures, but presume
hat the rate of continuing reaction and further modiﬁcation in the
yophilized state would be signiﬁcantly slower at 4 ◦C.
. Discussion
We  were surprised to ﬁnd that formaldehyde-treated mTcdB
amples which had obviously reverted to toxicity (killed mice in the
n-vivo mouse toxicity assay) were not detected as being toxic in
he cell-based toxicity assay. The cell-based toxicity assay appeared
o work well for samples before formaldehyde treatment, but
as ineffective at detecting reversion to toxicity of formaldehyde-
reated mTcdB samples. However, we found that for mTcdB treated
ith formaldehyde (without lysine), the retention time on AEX3 (2015) 252–259
chromatography was  sensitive to the time/extent of the formalde-
hyde detoxiﬁcation reaction, and the shift in the retention time
peak correlated with reversion and mouse deaths. The correlation
did not apply when mTcdB was treated with formaldehyde plus
30 mM lysine, which may  be due to competing, complex effects on
the net charge of the toxoid. Similarly, we found that SDS-PAGE
could also be used to monitor the forward and reverse reactions of
formaldehyde with mTcdB.
Storing liquid formulations of formaldehyde-treated mTcdB at
refrigerated temperatures slows but does not prevent reversion
of the AEX retention time, which we consider a useful marker
for reversion to toxicity. For long term storage of C. difﬁcile tox-
oid antigens in liquid formulations, adding back a low level of
formaldehyde has been found to prevent reversion to toxicity [26].
This approach has been suggested for a C. difﬁcile toxoid vaccine
[31], and recently described for an unidentiﬁed lyophilized toxoid
vaccine [32]. However, inclusion of 0.016% formaldehyde in that
unidentiﬁed lyophilized vaccine appears to have had some nega-
tive impact on the toxoid antigen (see Figure 9 of Ref. [32]), leading
to loss of protein concentration as measured by HPLC with ﬂuores-
cence detection. Maybe the effect of formaldehyde in that case was
to cause, over time in the lyophilized state, changes to the antigen
that resulted in failure of aggregated antigen to enter the HPLC col-
umn. That would be consistent with our ﬁnding that low levels of
formaldehyde can continue to react with and modify antigens in the
lyophilized state, and similar phenomena that have been described
in the past [33]. In our work, we  found that when a lyophilized
mTcdB toxoid sample with 0.016% formaldehyde was  stored at
37 ◦C, the formaldehyde continued to progressively modify the
antigen in the lyophilized state. While it is likely that storage of
the lyophilized antigen with 0.016% formaldehyde at a lower tem-
perature would slow the reaction considerably, and it is possible
that the moisture content of lyophilized samples may  inﬂuence this
reaction, the recognition that adding a low level of formaldehyde
and lyophilizing does not just “freeze” the state of the detoxiﬁed
antigen but could cause further changes to mTcdB over time is of
at least theoretical concern. It did not appear necessary to include
a low level of formaldehyde with the lyophilized mTcdB antigen to
prevent reversion to toxicity. By several measures, mTcdB rever-
sion did not occur over 6 months with storage at 37 ◦C. However,
inclusion of formaldehyde in the case of a C. difﬁcile toxoid vaccine
based on the wild type toxins might be necessary and advisable,
as the potential exists for many additional orders of magnitude of
increased toxicity compared to mTcdB.
5. Conclusion
Based on our work, we suggest that an effective approach to
removing the residual toxicity of mTcdB and avoiding reversion
to toxicity is formaldehyde treatment (for example, with 0.45%
v/v formaldehyde for 1–3 days at room temperature, with no
added amino acid necessary), dialysis or otherwise removal of the
formaldehyde, lyophilization of the toxoid antigen, and use within
a short period of time after reconstitution.
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